Prospective Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia with Inversion(16) by CBFβ/MYH11 RT-PCR: Implications for a Monitoring Schedule and for Treatment Decisions

Minimal residual disease in patients with acute myeloid leukemia (AML) with inversion(16) can be monitored by CBFβ/MYH11 RT-PCR. While the association between molecular remission (MR) in bone marrow (BM) and peripheral blood (PB) and long-term clinical remission (CR) seems to be established, there a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Leukemia & lymphoma 2001, Vol.42 (5), p.923-931
Hauptverfasser:	Laczika, Klaus, Mitterbauer, Gerlinde, Mitterbauer, Margit, Knöbl, Paul, Schwarzinger, Ilse, Greinix, Hildegard T., Rabitsch, Werner, Fonatsch, Christa, Mannhalter, Christine, Lechner, Klaus, Jaeger, Ulrich
Format:	Artikel
Sprache:	eng
Schlagworte:	AML CBFβ/MYH11 RT-PCR immunotherapy inversion minimal residual disease relapse prediction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!